FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2512939488> ?p ?o ?g. }

• W2512939488 abstract "Abstract Introduction Rituximab has markedly improved the clinical outcomes of mature B cell lymphoma, and rituximab maintenance therapy has been shown to be beneficial, especially in low grade B cell lymphoma (LGBCL). Several studies evaluated intensified rituximab administration combined with chemotherapy. But so far, there has not been any trial of rituximab mono-therapy with intensive rituximab induction followed by maintenance. A multicenter, phase II trial was conducted to evaluate the efficacy and safety of rituximab as induction, weekly 8 doses, and maintenance therapy for 2 years for LGBCL. Patients and Methods Patients with measurable LGBCL according to the World Health Organization (WHO) classification (2001) without prior rituximab treatment and staged as II, II, or IV by Ann-Arbor, were eligible. Patients received rituximab (375 mg/m2) weekly for 8 weeks as induction therapy, and then patients who did not have progressive disease at the end of induction received maintenance therapy with 4 weeks of rituximab at six-month intervals (up to 2 years or disease progression). Duration of treatment was 2.5 years in total. The primary endpoint was the best overall response rate (ORR). The secondary endpoints were complete response rate (CRR), 3-year progression free survival (PFS), 3-year overall survival (OS), and safety. Survivals were assessed using the Kaplan-Meier method. Results Forty-one patients with a median age of 64 years (41 to 79) were enrolled at 12 institutes belonging to the Clinical Hematology Group of National Hospital Organization (CHG-NHO) of Japan from December 2005 to May 2009. The majority of disease histology was follicular lymphoma in 33 patients. Of 41 patients, 15 were diagnosed as high tumor burden based on GELF criteria, and FLIP risk grouping classified all into 12 low risk, 21 intermediate risk, and 12 high risk cases. Four relapsed cases were included, and they have all received prior systemic chemotherapy without rituximab. Of the 41 patients, 31 (75.6%) completed the planned 2.5 years therapy. The best ORR was 75.6% (31/41, 90% CI: 62.2-86.1%), with 63.4% CR. Three-year PFS at a median follow-up time of 43.0 months (5.3-72) was 79.7% (90% CI, 66.6-88.1%). Three-year OS at a median follow-up time of 49.4 months (5.3-72) was 97.4% (90% CI, 87.1-99.5%). Grade 3 toxicities were neutropenia in 2.5% (1/41), elevated ALT in 2.5% (1/41), and infection in 2.5% (1/41). There was no grade 4 toxicity. Conclusions Intensified rituximab induction and maintenance therapy was demonstrated to have high activity, with durable PFS and minimum toxicity in LGBCL patients. Although a further large-scale trial is needed, intensified rituximab induction followed by rituximab maintenance could be a good treatment in rituximab naïve LGBCL. Disclosures: No relevant conflicts of interest to declare." @default.
• W2512939488 created "2016-09-16" @default.
• W2512939488 creator A5019098042 @default.
• W2512939488 creator A5019777938 @default.
• W2512939488 creator A5021156520 @default.
• W2512939488 creator A5028451977 @default.
• W2512939488 creator A5030224295 @default.
• W2512939488 creator A5036324396 @default.
• W2512939488 creator A5039755665 @default.
• W2512939488 creator A5041678137 @default.
• W2512939488 creator A5047026314 @default.
• W2512939488 creator A5051701709 @default.
• W2512939488 creator A5055831731 @default.
• W2512939488 creator A5060215509 @default.
• W2512939488 creator A5086772095 @default.
• W2512939488 creator A5088100950 @default.
• W2512939488 creator A5088318325 @default.
• W2512939488 date "2013-11-15" @default.
• W2512939488 modified "2023-10-01" @default.
• W2512939488 title "Intensified Rituximab Induction Followed By Rituximab Maintenance For Low Grade B Cell Lymphoma: A Multicenter, Phase II Study" @default.
• W2512939488 doi "https://doi.org/10.1182/blood.v122.21.1797.1797" @default.
• W2512939488 hasPublicationYear "2013" @default.
• W2512939488 type Work @default.
• W2512939488 sameAs 2512939488 @default.
• W2512939488 citedByCount "0" @default.
• W2512939488 crossrefType "journal-article" @default.
• W2512939488 hasAuthorship W2512939488A5019098042 @default.
• W2512939488 hasAuthorship W2512939488A5019777938 @default.
• W2512939488 hasAuthorship W2512939488A5021156520 @default.
• W2512939488 hasAuthorship W2512939488A5028451977 @default.
• W2512939488 hasAuthorship W2512939488A5030224295 @default.
• W2512939488 hasAuthorship W2512939488A5036324396 @default.
• W2512939488 hasAuthorship W2512939488A5039755665 @default.
• W2512939488 hasAuthorship W2512939488A5041678137 @default.
• W2512939488 hasAuthorship W2512939488A5047026314 @default.
• W2512939488 hasAuthorship W2512939488A5051701709 @default.
• W2512939488 hasAuthorship W2512939488A5055831731 @default.
• W2512939488 hasAuthorship W2512939488A5060215509 @default.
• W2512939488 hasAuthorship W2512939488A5086772095 @default.
• W2512939488 hasAuthorship W2512939488A5088100950 @default.
• W2512939488 hasAuthorship W2512939488A5088318325 @default.
• W2512939488 hasConcept C126322002 @default.
• W2512939488 hasConcept C141071460 @default.
• W2512939488 hasConcept C143998085 @default.
• W2512939488 hasConcept C203092338 @default.
• W2512939488 hasConcept C2776694085 @default.
• W2512939488 hasConcept C2778283404 @default.
• W2512939488 hasConcept C2779338263 @default.
• W2512939488 hasConcept C2780653079 @default.
• W2512939488 hasConcept C2780739268 @default.
• W2512939488 hasConcept C31760486 @default.
• W2512939488 hasConcept C535046627 @default.
• W2512939488 hasConcept C71924100 @default.
• W2512939488 hasConceptScore W2512939488C126322002 @default.
• W2512939488 hasConceptScore W2512939488C141071460 @default.
• W2512939488 hasConceptScore W2512939488C143998085 @default.
• W2512939488 hasConceptScore W2512939488C203092338 @default.
• W2512939488 hasConceptScore W2512939488C2776694085 @default.
• W2512939488 hasConceptScore W2512939488C2778283404 @default.
• W2512939488 hasConceptScore W2512939488C2779338263 @default.
• W2512939488 hasConceptScore W2512939488C2780653079 @default.
• W2512939488 hasConceptScore W2512939488C2780739268 @default.
• W2512939488 hasConceptScore W2512939488C31760486 @default.
• W2512939488 hasConceptScore W2512939488C535046627 @default.
• W2512939488 hasConceptScore W2512939488C71924100 @default.
• W2512939488 hasLocation W25129394881 @default.
• W2512939488 hasOpenAccess W2512939488 @default.
• W2512939488 hasPrimaryLocation W25129394881 @default.
• W2512939488 hasRelatedWork W1985867079 @default.
• W2512939488 hasRelatedWork W2206889833 @default.
• W2512939488 hasRelatedWork W2212577719 @default.
• W2512939488 hasRelatedWork W2379269917 @default.
• W2512939488 hasRelatedWork W2426182124 @default.
• W2512939488 hasRelatedWork W2524130482 @default.
• W2512939488 hasRelatedWork W2550784115 @default.
• W2512939488 hasRelatedWork W2557062468 @default.
• W2512939488 hasRelatedWork W2562143240 @default.
• W2512939488 hasRelatedWork W2567356147 @default.
• W2512939488 hasRelatedWork W2575542121 @default.
• W2512939488 hasRelatedWork W2580098189 @default.
• W2512939488 hasRelatedWork W2584595082 @default.
• W2512939488 hasRelatedWork W2585109591 @default.
• W2512939488 hasRelatedWork W2588301057 @default.
• W2512939488 hasRelatedWork W2605882989 @default.
• W2512939488 hasRelatedWork W2610259949 @default.
• W2512939488 hasRelatedWork W2779713036 @default.
• W2512939488 hasRelatedWork W2979675793 @default.
• W2512939488 hasRelatedWork W2980850779 @default.
• W2512939488 isParatext "false" @default.
• W2512939488 isRetracted "false" @default.
• W2512939488 magId "2512939488" @default.
• W2512939488 workType "article" @default.